ClinVar Miner

Submissions for variant NM_007373.4(SHOC2):c.4A>G (p.Ser2Gly)

gnomAD frequency: 0.00001  dbSNP: rs267607048
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 41
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen RASopathy Variant Curation Expert Panel RCV000007223 SCV000616382 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2017-04-03 reviewed by expert panel curation The c.4A>G (p.Ser2Gly) variant in SHOC2 has been reported as a confirmed de novo occurrence in multiple patients with clinical features of a RASopathy (PS2_VeryStrong; Partners LMM, Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert Debré Hospital internal data; GTR ID's: 21766, 506381, 28338; ClinVar SCV000062456.5, SCV000209051.10, SCV000263045.1 PMID 19684605, 21548061, 23918763, 22528146). The p.Ser2Gly variant has been identified in at least 5 independent occurrences in patients with clinical features of a RASopathy (PS4; Institute of Human Genetics, Otto von Guericke University Magdeburg, APHP-Robert Debré Hospital internal data GTR ID's: 506381, 28338; PMID: 25563136, 24458587). In vitro functional studies provide some evidence that the p.Ser2Gly variant may impact protein function (PS3; PMID: 19684605). This variant was absent from large population studies (PM2; ExAC, http://exac.broadinstitute.org). The variant is located in the SHOC2 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS3, PS4, PM2, PP2.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000208379 SCV000062456 pathogenic Noonan syndrome 2014-12-03 criteria provided, single submitter clinical testing The p.Ser2Gly variant in SHOC2 is an established pathogenic variant for Noonan s yndrome with loose anagen hair. The variant was identified in >40 affected indiv iduals across multiple studies and in multiple cases was shown to be de novo (Co rdeddu 2009, Komatsuzaki 2010, Gripp 2013, LMM data). It has not been identified large population studies. In vitro functional studies provide some evidence tha t the p.Ser2Gly variant impacts protein function (Cordeddu 2009). In summary, th is variant meets our criteria to be classified as pathogenic for Noonan syndrome in an autosomal dominant manner.
GeneDx RCV000213000 SCV000209051 pathogenic not provided 2020-05-18 criteria provided, single submitter clinical testing Located in the critical functional domain S2 and inhibits SHOC2 function by impairing proper cellular localization of the protein (Galperin et al., 2012); In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25858597, 22419608, 26350204, 24803665, 31501239, 19684605, 22606262, 25846317, 25563136, 21548061, 24033266, 25326637, 24458596, 24458587, 25331583, 23918763, 25123707, 26096762, 22528146, 26607044, 26519477, 20882035, 22995099, 28680615, 28554332, 24124081, 29737035, 29948256, 30732632, 30240112, 30417923, 30050098, 29907801, 31219622, 30962759, 31584751, 31628766, 31019026, 32005694, 33318624, 34008892, 33300679, 33502061, 32978145, 33240318, 32870709, 34006472, 31785789)
Genetic Services Laboratory, University of Chicago RCV000007223 SCV000248876 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2015-03-13 criteria provided, single submitter clinical testing
Invitae RCV000149834 SCV000253914 pathogenic RASopathy 2024-01-22 criteria provided, single submitter clinical testing This sequence change replaces serine, which is neutral and polar, with glycine, which is neutral and non-polar, at codon 2 of the SHOC2 protein (p.Ser2Gly). This variant is present in population databases (rs267607048, gnomAD 0.007%). This missense change has been observed in individual(s) with Noonan-like syndrome with loose anagen hair (PMID: 19684605, 20882035, 22995099, 23918763, 25123707, 25331583). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 6821). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects SHOC2 function (PMID: 19684605, 22606262). For these reasons, this variant has been classified as Pathogenic.
UCLA Clinical Genomics Center, UCLA RCV000007223 SCV000255466 likely pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2013-11-26 criteria provided, single submitter clinical testing
Molecular Diagnostics Lab, Nemours Children's Health, Delaware RCV000007223 SCV000263045 likely pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2015-07-20 criteria provided, single submitter clinical testing
Blueprint Genetics RCV000208379 SCV000264222 pathogenic Noonan syndrome 2015-01-26 criteria provided, single submitter clinical testing
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000007223 SCV000265524 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2014-09-11 criteria provided, single submitter research
Eurofins Ntd Llc (ga) RCV000213000 SCV000332269 pathogenic not provided 2015-06-15 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000007223 SCV000605107 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2023-05-28 criteria provided, single submitter clinical testing The SHOC2 c.4A>G; p.Ser2Gly variant (rs267607048) has been reported in multiple individuals diagnosed with Noonan-like syndrome with loose anagen hair, and often identified as a de novo alteration (Cordeddu 2009, Komatsuzaki 2010, Ekvall 2011, Gripp 2013, Baldassare 2014). Functional characterization of the p.Ser2Gly protein indicates enhanced myristoylation, and aberrant targeting of the SHOC2 to the cell membrane in the absence of growth factor signaling (Cordeddu 2009). This results in an increase in basal and growth-factor stimulated ERK phosphorylation (Cordeddu 2009), consistent with the established disease mechanisms. The variant is classified as pathogenic by many sources in the ClinVar database (Variation ID: 6821) is only observed on one allele in the Genome Aggregation Database, indicating it is not a common polymorphism. Based on available information, this variant is classified as pathogenic. References: Baldassarre G et al. Phenotypic variability associated with the invariant SHOC2 c.4A>G (p.Ser2Gly) missense mutation. Am J Med Genet A. 2014 Dec;164A(12):3120-5. PMID: 25331583. Cordeddu V et al. Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet. 2009 Sep;41(9):1022-6. PMID: 19684605. Ekvall S et al. Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype. Am J Med Genet A. 2011 Jun;155A(6):1217-24. PMID: 21548061. Gripp KW et al. Expanding the SHOC2 mutation associated phenotype of Noonan syndrome with loose anagen hair: structural brain anomalies and myelofibrosis. Am J Med Genet A. 2013 Oct;161A(10):2420-30. PMID: 23918763. Komatsuzaki S et al. Mutation analysis of the SHOC2 gene in Noonan-like syndrome and in hematologic malignancies. J Hum Genet. 2010 Dec;55(12):801-9. PMID: 20882035.
Fulgent Genetics, Fulgent Genetics RCV000007223 SCV000611318 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2017-05-18 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000149834 SCV000699328 pathogenic RASopathy 2019-10-26 criteria provided, single submitter clinical testing Variant summary: SHOC2 c.4A>G (p.Ser2Gly) results in a non-conservative amino acid change in the encoded protein sequence, located in the N-terminal region. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 248040 control chromosomes. The variant has been reported in literature as one of the most recurrent mutations found in patients with NS or NS-related disorders. It is predominantly found in patients with Noonan-like syndrome with loose anagen hair. The variant was proven to be de novo in multiple patients strongly supporting its pathogenicity. From functional studies this variant was found to introduce an N-myristoylation site, resulting in aberrant targeting of SHOC2 to the plasma membrane and impaired translocation to the nucleus upon growth factor stimulation. Expression of SHOC2-S2G in vitro enhanced MAPK activation in a cell type specific fashion. Induction of SHOC2-S2G in Caenorhabditis elegans engendered protruding vulva, a neomorphic phenotype associated with aberrant signaling (Cordeddu_2009). In other functional study, the SHOC2-S2G mutant did not rescue ERK1/2 activation in Shoc2-depleted cells and the mutant was not located in late endosomes, however it was present on the plasma membrane and early endosomes (Galperin_2012). 13 clinical diagnostic laboratories (including one expert panel) have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic/likely pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic.
Ambry Genetics RCV000624656 SCV000741813 pathogenic Inborn genetic diseases 2017-02-23 criteria provided, single submitter clinical testing
Baylor Genetics RCV000007223 SCV000807267 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2021-02-16 criteria provided, single submitter clinical testing
Laboratory of Molecular Genetics (Pr. Bezieau's lab), CHU de Nantes RCV000213000 SCV000920499 pathogenic not provided 2018-07-19 criteria provided, single submitter clinical testing
Equipe Genetique des Anomalies du Developpement, Université de Bourgogne RCV000007223 SCV000965711 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2015-01-01 criteria provided, single submitter clinical testing
Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego RCV000853278 SCV000996110 pathogenic Noonan syndrome-like disorder with loose anagen hair 2018-02-22 criteria provided, single submitter clinical testing This variant has been previously reported as a de novo change in multiple unrelated patients with Noonan-like syndrome with loose anagen hair (PMID: 19684605, 25331583). This variant has been classified in ClinVar as pathogenic by the ClinGen Rasopathy Expert Panel and by several clinical diagnostic laboratories (https://www.ncbi.nlm.nih.gov/clinvar/variation/6821/). It is present in one heterozygote in the gnomAD population database and thus is presumed to be rare. Analysis of the parental samples was negative for the variant, indicating this variant likely occurred as a de novo event. Based on the available evidence, this variant is classified as pathogenic.
CeGaT Center for Human Genetics Tuebingen RCV000213000 SCV001246712 pathogenic not provided 2022-01-01 criteria provided, single submitter clinical testing
Centre for Mendelian Genomics, University Medical Centre Ljubljana RCV000007223 SCV001367708 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2018-11-21 criteria provided, single submitter clinical testing This variant was classified as: Pathogenic. The following ACMG criteria were applied in classifying this variant: PS3,PM2,PP2,PP3,PP4,PP5.
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV000213000 SCV001447732 pathogenic not provided 2020-10-23 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000213000 SCV001714366 pathogenic not provided 2019-09-09 criteria provided, single submitter clinical testing PS2, PS3, PS4, PM6_Strong, PM1, PP2
Laboratory of Medical Genetics, National & Kapodistrian University of Athens RCV000007223 SCV001976983 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2021-10-01 criteria provided, single submitter clinical testing PS2, PM2, PP3, PP5
Al Jalila Children's Genomics Center, Al Jalila Childrens Speciality Hospital RCV000007223 SCV001984384 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2021-02-18 criteria provided, single submitter clinical testing
3billion RCV000007223 SCV002012001 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2021-10-02 criteria provided, single submitter clinical testing Same nucleotide change resulting in same amino acid change has been previously reported multiple times as de novo in similarly affected indivisual (PMID: 22528146, 21548061, 23918763, 19684605, 25563136, 24458587, PS2, PS4). Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID: 19684605, PS3). The missense variant is located in a mutational hot spot and/or well-established functional domain in which established pathogenic variants have been reported (PM1).It is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.0000319, PM2). The variant was observed as assumed (i.e. paternity and maternity not confirmed) de novoo (3billion dataset, PM6). Therefore, this variant is classified as pathogenic according to the recommendation of ACMG/AMP guideline.
Centogene AG - the Rare Disease Company RCV000007223 SCV002059626 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2021-01-13 criteria provided, single submitter clinical testing
Genome Diagnostics Laboratory, The Hospital for Sick Children RCV001813181 SCV002060971 pathogenic Noonan syndrome and Noonan-related syndrome 2021-01-08 criteria provided, single submitter clinical testing
Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center RCV002221469 SCV002499159 pathogenic Polycystic kidney disease 4 2022-03-30 criteria provided, single submitter clinical testing PS2, PS4, PM2
Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein RCV000007223 SCV002512520 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2021-08-16 criteria provided, single submitter clinical testing ACMG classification criteria: PS2 very strong, PS3 moderate, PS4 moderate, PM2 moderate, PP2 supporting
Genomic Medicine Lab, University of California San Francisco RCV000007223 SCV002576361 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 criteria provided, single submitter clinical testing
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV000007223 SCV002767174 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2020-10-19 criteria provided, single submitter clinical testing Based on the classification scheme VCGS_Germline_v1.3.3, this variant is classified as Pathogenic. Following criteria are met: 0101 - Gain of function is a known mechanism of disease in this gene and is associated with Noonan syndrome-like with loose anagen hair (MIM#607721). Missense variants in this gene result in enhanced MAPK activation (OMIM, PMID: 19684605). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from serine to glycine. (I) 0251 - This variant is heterozygous. (I) 0302 - Variant is present in gnomAD <0.001 for a dominant condition (1 heterozygote, 0 homozygotes). (SP) 0502 - Missense variant with conflicting in silico predictions and uninformative conservation. (I) 0604 - Variant is not located in an established domain, motif, hotspot or informative constraint region. (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported many times as pathogenic, and is observed in de novo patients with RASopathy (ClinVar, PMID: 25331583). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Functional studies have demonstrated this variant causes impaired nuclear translocation and MAPK activation (PMID: 19684605). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign
Athena Diagnostics RCV000213000 SCV002817221 pathogenic not provided 2020-05-15 criteria provided, single submitter clinical testing This variant has been confirmed to occur de novo in multiple individuals with clinical features associated with this gene (PMID: 19684605, 25846317, 25331583, 25123707). The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). Assessment of experimental evidence suggests this variant results in abnormal protein function (PMID: 19684605, 22606262).This observation is not an independent occurrence and has been identified in the same individual by RCIGM, the other laboratory participating in the GEMINI study.
Division of Human Genetics, National Health Laboratory Service/University of the Witwatersrand RCV000007223 SCV004024492 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2023-07-01 criteria provided, single submitter research
Institute for Medical Genetics and Human Genetics, Charité - Universitätsmedizin Berlin RCV003330311 SCV004037443 pathogenic Pectus excavatum; Noonan syndrome-like disorder with loose anagen hair 1 criteria provided, single submitter not provided
Neuberg Centre For Genomic Medicine, NCGM RCV000007223 SCV004171888 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 criteria provided, single submitter clinical testing The missense c.4A>G(p.Ser2Gly) variant in SHOC2 gene has been reported previously in individual(s) affected with Noonan syndrome with loose anagen hair (Gripp KW, et. al., 2013; Choi JH, et. al., 2015). Functional studies indicate that this variant has a damaging effect on the gene or the gene product (Cordeddu V, et. al., 2009). The p.Ser2Gly variant is novel (not in any individuals) in both gnomAD Exomes and 1000 Genomes databases. This variant has been submitted to ClinVar database as Likely Pathogenic / Pathogenic (multiple submissions). The amino acid change p.Ser2Gly in SHOC2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Ser at position 2 is changed to a Gly changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Pathogenic.
Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center RCV000007223 SCV004805081 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2024-03-17 criteria provided, single submitter research
OMIM RCV000007223 SCV000027419 pathogenic Noonan syndrome-like disorder with loose anagen hair 1 2013-10-01 no assertion criteria provided literature only
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) RCV000007223 SCV000143830 not provided Noonan syndrome-like disorder with loose anagen hair 1 no assertion provided not provided
Baylor Genetics RCV000149834 SCV000196678 pathogenic RASopathy no assertion criteria provided clinical testing Variant classified using ACMG guidelines
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ RCV000213000 SCV001959945 pathogenic not provided no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000213000 SCV001967844 pathogenic not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.